Linking anemia to inflammation and cancer: The crucial role of TNFα

Biochemical Pharmacology

Volumn 77, Issue 10, 2009, Pages 1572-1579

  Buck, Isabelle ^a   Morceau, Franck ^a   Grigorakaki, Christina ^a   Dicato, Mario ^a   Diederich, Marc ^a  

^a LABORATOIRE DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE DU CANCER   (Luxembourg)

Author keywords

Cancer; Erythroid differentiation; Erythropoietin; Inflammation; TNF

Indexed keywords

ADALIMUMAB; ERYTHROID KRUPPEL LIKE FACTOR; ERYTHROPOIETIN; ETANERCEPT; HEMOGLOBIN; HISTONE ACETYLTRANSFERASE PCAF; INFLIXIMAB; MITOGEN ACTIVATED PROTEIN KINASE P38; N [4 [2 ETHYL 4 (3 METHYLPHENYL) 1,3 THIAZOL 5 YL] 2 PYRIDYL]BENZAMIDE; PROTEIN C MYB; RECOMBINANT ERYTHROPOIETIN; TAK 715; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR GATA 2; TRANSCRIPTION FACTOR NRF1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ANEMIA; APOPTOSIS; ARTICLE; ASBESTOSIS; BLOOD TRANSFUSION; BREAST CANCER; CANCER GROWTH; CANCER INVASION; CANCER PATIENT; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL LINEAGE; CROHN DISEASE; DIABETIC PATIENT; DIABETIC RETINOPATHY; ERYTHROPOIESIS; GENE OVEREXPRESSION; GENERAL CONDITION DETERIORATION; HEMATOPOIETIC STEM CELL; HEPATITIS C; HUMAN; INFLAMMATORY DISEASE; KIDNEY CANCER; LIVER CARCINOGENESIS; MULTIPOTENT STEM CELL; NONHUMAN; PANCREATITIS; PATHOPHYSIOLOGY; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; SURVIVAL TIME;

EID: 64049106896     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.12.018     Document Type: Note

References (88)

1. Balkwill F., Charles K.A., and Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7 (2005) 211-217
2. Balkwill F., and Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 357 (2001) 539-545
3. Coussens L.M., and Werb Z. Inflammation and cancer. Nature 420 (2002) 860-867
4. Greten F.R., Eckmann L., Greten T.F., Park J.M., Li Z.W., Egan L.J., et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118 (2004) 285-296
5. Pikarsky E., Porat R.M., Stein I., Abramovitch R., Amit S., Kasem S., et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431 (2004) 461-466
6. Szlosarek P.W., and Balkwill F.R. Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol 4 (2003) 565-573
7. Szlosarek P., Charles K.A., and Balkwill F.R. Tumour necrosis factor-alpha as a tumour promoter. Eur J Cancer 42 (2006) 745-750
8. Yan L., Anderson G.M., DeWitte M., and Nakada M.T. Therapeutic potential of cytokine and chemokine antagonists in cancer therapy. Eur J Cancer 42 (2006) 793-802
9. Bokemeyer C., Oechsle K., and Hartmann J.T. Anaemia in cancer patients: pathophysiology, incidence and treatment. Eur J Clin Invest 35 Suppl 3 (2005) 26-31
10. Allen D.A., Breen C., Yaqoob M.M., and Macdougall I.C. Inhibition of CFU-E colony formation in uremic patients with inflammatory disease: role of IFN-gamma and TNF-alpha. J Invest Med 47 (1999) 204-211
11. Papadaki H.A., Kritikos H.D., Valatas V., Boumpas D.T., and Eliopoulos G.D. Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor-alpha antibody therapy. Blood 100 (2002) 474-482
12. Robb L. Cytokine receptors and hematopoietic differentiation. Oncogene 26 (2007) 6715-6723
13. Wickrema A., and Crispino J.D. Erythroid and megakaryocytic transformation. Oncogene 26 (2007) 6803-6815
14. Hodges V.M., Rainey S., Lappin T.R., and Maxwell A.P. Pathophysiology of anemia and erythrocytosis. Crit Rev Oncol Hematol 64 (2007) 139-158
15. Zhao W., Kitidis C., Fleming M.D., Lodish H.F., and Ghaffari S. Erythropoietin stimulates phosphorylation and activation of GATA-1 via the PI3-kinase/AKT signaling pathway. Blood 107 (2006) 907-915
16. Wall L., deBoer E., and Grosveld F. The human beta-globin gene 3′ enhancer contains multiple binding sites for an erythroid-specific protein. Genes Dev 2 (1988) 1089-1100
17. Merika M., and Orkin S.H. DNA-binding specificity of GATA family transcription factors. Mol Cell Biol 13 (1993) 3999-4010
18. Morceau F., Schnekenburger M., Dicato M., and Diederich M. GATA-1: friends, brothers, and coworkers. Ann N Y Acad Sci 1030 (2004) 537-554
19. Ferreira R., Ohneda K., Yamamoto M., and Philipsen S. GATA1 function, a paradigm for transcription factors in hematopoiesis. Mol Cell Biol 25 (2005) 1215-1227
20. Fujiwara Y., Browne C.P., Cunniff K., Goff S.C., and Orkin S.H. Arrested development of embryonic red cell precursors in mouse embryos lacking transcription factor GATA-1. Proc Natl Acad Sci USA 93 (1996) 12355-12358
21. Pevny L., Simon M.C., Robertson E., Klein W.H., Tsai S.F., D'Agati V., et al. Erythroid differentiation in chimaeric mice blocked by a targeted mutation in the gene for transcription factor GATA-1. Nature 349 (1991) 257-260
22. Rekhtman N., Radparvar F., Evans T., and Skoultchi A.I. Direct interaction of hematopoietic transcription factors PU.1 and GATA-1: functional antagonism in erythroid cells. Genes Dev 13 (1999) 1398-1411
23. Grass J.A., Boyer M.E., Pal S., Wu J., Weiss M.J., and Bresnick E.H. GATA-1-dependent transcriptional repression of GATA-2 via disruption of positive autoregulation and domain-wide chromatin remodelling. Proc Natl Acad Sci USA 100 (2003) 8811-8816
24. Andrews N.C., Erdjument-Bromage H., Davidson M.B., Tempst P., and Orkin S.H. Erythroid transcription factor NF-E2 is a haematopoietic-specific basic-leucine zipper protein. Nature 362 (1993) 722-728
25. Lu S.J., Rowan S., Bani M.R., and Ben-David Y. Retroviral integration within the Fli-2 locus results in inactivation of the erythroid transcription factor NF-E2 in Friend erythroleukemias: evidence that NF-E2 is essential for globin expression. Proc Natl Acad Sci USA 91 (1994) 8398-8402
26. Perkins A.C., Peterson K.R., Stamatoyannopoulos G., Witkowska H.E., and Orkin S.H. Fetal expression of a human Agamma globin transgene rescues globin chain imbalance but not hemolysis in EKLF null mouse embryos. Blood 95 (2000) 1827-1833
27. Carswell E.A., Old L.J., Kassel R.L., Green S., Fiore N., and Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 72 (1975) 3666-3670
28. Aggarwal B.B. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 3 (2003) 745-756
29. Aggarwal B.B., Shishodia S., Sandur S.K., Pandey M.K., and Sethi G. Inflammation and cancer: how hot is the link?. Biochem Pharmacol 72 (2006) 1605-1621
30. Pfeffer K. Biological functions of tumor necrosis factor cytokines and their receptors. Cytokine Growth Factor Rev 14 (2003) 185-191
31. Feldmann M., Brennan F.M., and Maini R.N. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14 (1996) 397-440
32. Knobler H., and Schattner A. TNF-{alpha}, chronic hepatitis C and diabetes: a novel triad. QJM 98 (2005) 1-6
33. Targan S.R., Hanauer S.B., van Deventer S.J., Mayer L., Present D.H., Braakman T., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 337 (1997) 1029-1035
34. Limb G.A., Chignell A.H., Green W., LeRoy F., and Dumonde D.C. Distribution of TNF alpha and its reactive vascular adhesion molecules in fibrovascular membranes of proliferative diabetic retinopathy. Br J Ophthalmol 80 (1996) 168-173
35. Friess H., Guo X.Z., Nan B.C., Kleeff O., and Buchler M.W. Growth factors and cytokines in pancreatic carcinogenesis. Ann N Y Acad Sci 880 (1999) 110-121
36. Haraoui B. Differentiating the efficacy of tumor necrosis factor inhibitors. J Rheumatol Suppl 74 (2005) 3-7
37. Haraoui B. The anti-tumor necrosis factor agents are a major advance in the treatment of rheumatoid arthritis. J Rheumatol Suppl 72 (2005) 46-47
38. Broxmeyer H.E., Williams D.E., Lu L., Cooper S., Anderson S.L., Beyer G.S., et al. The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-gamma. J Immunol 136 (1986) 4487-4495
39. Murase T., Hotta T., Saito H., and Ohno R. Effect of recombinant human tumor necrosis factor on the colony growth of human leukemia progenitor cells and normal hematopoietic progenitor cells. Blood 69 (1987) 467-472
40. Rusten L.S., Smeland E.B., Jacobsen F.W., Lien E., Lesslauer W., Loetscher H., et al. Tumor necrosis factor-alpha inhibits stem cell factor-induced proliferation of human bone marrow progenitor cells in vitro. Role of p55 and p75 tumor necrosis factor receptors. J Clin Invest 94 (1994) 165-172
41. Rusten L.S., and Jacobsen S.E. Tumor necrosis factor (TNF)-alpha directly inhibits human erythropoiesis in vitro: role of p55 and p75 TNF receptors. Blood 85 (1995) 989-996
42. Means Jr. R.T., Dessypris E.N., and Krantz S.B. Inhibition of human colony-forming-unit erythroid by tumor necrosis factor requires accessory cells. J Clin Invest 86 (1990) 538-541
43. Means Jr. R.T., and Krantz S.B. Inhibition of human erythroid colony-forming units by tumor necrosis factor requires beta interferon. J Clin Invest 91 (1993) 416-419
44. Balkwill F. Tumor necrosis factor or tumor promoting factor?. Cytokine Growth Factor Rev 13 (2002) 135-141
45. van Etten B., van Geel A.N., de Wilt J.H., and Eggermont A.M. Fifty tumor necrosis factor-based isolated limb perfusions for limb salvage in patients older than 75 years with limb-threatening soft tissue sarcomas and other extremity tumors. Ann Surg Oncol 10 (2003) 32-37
46. Mantovani G., Maccio A., Mura L., Massa E., Mudu M.C., Mulas C., et al. Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. J Mol Med 78 (2000) 554-561
47. Yoshida N., Ikemoto S., Narita K., Sugimura K., Wada S., Yasumoto R., et al. Interleukin-6, tumour necrosis factor alpha and interleukin-1beta in patients with renal cell carcinoma. Br J Cancer 86 (2002) 1396-1400
48. Leek R.D., Landers R., Fox S.B., Ng F., Harris A.L., and Lewis C.E. Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. Br J Cancer 77 (1998) 2246-2251
49. Partanen R., Koskinen H., and Hemminki K. Tumour necrosis factor-alpha (TNF-alpha) in patients who have asbestosis and develop cancer. Occup Environ Med 52 (1995) 316-319
50. Pfitzenmaier J., Vessella R., Higano C.S., Noteboom J.L., Wallace Jr. D., and Corey E. Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer 97 (2003) 1211-1216
51. Aggarwal B.B. Nuclear factor-kappaB: the enemy within. Cancer Cell 6 (2004) 203-208
52. Bossola M., Muscaritoli M., Bellantone R., Pacelli F., Cascino A., Sgadari A., et al. Serum tumour necrosis factor-alpha levels in cancer patients are discontinuous and correlate with weight loss. Eur J Clin Invest 30 (2000) 1107-1112
53. Chang I., Kim S., Kim J.Y., Cho N., Kim Y.H., Kim H.S., et al. Nuclear factor kappaB protects pancreatic beta-cells from tumor necrosis factor-alpha-mediated apoptosis. Diabetes 52 (2003) 1169-1175
54. Pahl H.L. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18 (1999) 6853-6866
55. Allavena P., Sica A., Solinas G., Porta C., and Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol 66 (2008) 1-9
56. Roodman G.D. Mechanisms of erythroid suppression in the anemia of chronic disease. Blood Cells 13 (1987) 171-184
57. Dufour C., Corcione A., Svahn J., Haupt R., Poggi V., Beka'ssy A.N., et al. TNF-alpha and IFN-gamma are overexpressed in the bone marrow of Fanconi anemia patients and TNF-alpha suppresses erythropoiesis in vitro. Blood 102 (2003) 2053-2059
58. Gersuk G.M., Beckham C., Loken M.R., Kiener P., Anderson J.E., Farrand A., et al. A role for tumour necrosis factor-alpha, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol 103 (1998) 176-188
59. Dufour C., Corcione A., Svahn J., Haupt R., Battilana N., and Pistoia V. Interferon gamma and tumour necrosis factor alpha are overexpressed in bone marrow T lymphocytes from paediatric patients with aplastic anaemia. Br J Haematol 115 (2001) 1023-1031
60. Imagawa S., Nakano Y., Obara N., Suzuki N., Doi T., Kodama T., et al. A GATA-specific inhibitor (K-7174) rescues anemia induced by IL-1beta, TNF-alpha, or L-NMMA. FASEB J 17 (2003) 1742-1744
61. Xiao W., Koizumi K., Nishio M., Endo T., Osawa M., Fujimoto K., et al. Tumor necrosis factor-alpha inhibits generation of glycophorin A+ cells by CD34+ cells. Exp Hematol 30 (2002) 1238-1247
62. Kurzrock R. The role of cytokines in cancer-related fatigue. Cancer 92 (2001) 1684-1688
63. Capalbo S., Battista C., Delia M., Ciancio A., De Santis G., Dargenio M., et al. Evaluation of tumor necrosis factor-alpha and erythropoietin serum levels in B-cell chronic lymphocytic leukemia patients with anemia. Acta Haematol 108 (2002) 84-89
64. Knight K., Wade S., and Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med 116 Suppl 7A (2004) 11S-26S
65. Tas F., Eralp Y., Basaran M., Sakar B., Alici S., Argon A., et al. Anemia in oncology practice: relation to diseases and their therapies. Am J Clin Oncol 25 (2002) 371-379
66. Caro J.J., Salas M., Ward A., and Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 91 (2001) 2214-2221
67. Pronzato P. Cancer-related anaemia management in the 21st century. Cancer Treat Rev 32 Suppl 2 (2006) S1-S3
68. Engert A. Recombinant human erythropoietin in oncology: current status and further developments. Ann Oncol 16 (2005) 1584-1595
69. Andrews N.C. Anemia of inflammation: the cytokine-hepcidin link. J Clin Invest 113 (2004) 1251-1253
70. Blau C.A. Erythropoietin in cancer: presumption of innocence?. Stem Cells 25 (2007) 2094-2097
71. Jelkmann W. Developments in the therapeutic use of erythropoiesis stimulating agents. Br J Haematol 141 (2008) 287-297
72. Rizzo J.D., Somerfield M.R., Hagerty K.L., Seidenfeld J., Bohlius J., Bennett C.L., et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood 111 (2008) 25-41
73. Henke M., Laszig R., Rube C., Schafer U., Haase K.D., Schilcher B., et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362 (2003) 1255-1260
74. Leyland-Jones B., Semiglazov V., Pawlicki M., Pienkowski T., Tjulandin S., Manikhas G., et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 23 (2005) 5960-5972
75. Wright J.R., Ung Y.C., Julian J.A., Pritchard K.I., Whelan T.J., Smith C., et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 25 (2007) 1027-1032
76. Jelkmann W. Control of erythropoietin gene expression and its use in medicine. Methods Enzymol 435 (2007) 179-197
77. Morceau F., Schnekenburger M., Blasius R., Buck I., Dicato M., and Diederich M. Tumor necrosis factor alpha inhibits aclacinomycin A-induced erythroid differentiation of K562 cells via GATA-1. Cancer Lett 240 (2006) 203-212
78. Buck I., Morceau F., Cristofanon S., Heintz C., Chateauvieux S., Reuter S., et al. Tumor necrosis factor alpha inhibits erythroid differentiation in human erythropoietin-dependent cells involving p38 MAPK pathway, GATA-1 and FOG-1 downregulation and GATA-2 upregulation. Biochem Pharmacol 76 (2008) 1229-1239
79. Buck I., Morceau F., Cristofanon S., Reuter S., Dicato M., and Diederich M. The inhibitory effect of the proinflammatory cytokine TNFalpha on erythroid differentiation involves erythroid transcription factor modulation. Int J Oncol 34 (2009) 853-860
80. Miwatashi S., Arikawa Y., Kotani E., Miyamoto M., Naruo K., Kimura H., et al. Novel inhibitor of p38 MAP kinase as an anti-TNF-alpha drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent. J Med Chem 48 (2005) 5966-5979
81. Koury M.J., Sawyer S.T., and Brandt S.J. New insights into erythropoiesis. Curr Opin Hematol 9 (2002) 93-100
82. Tsai F.Y., and Orkin S.H. Transcription factor GATA-2 is required for proliferation/survival of early hematopoietic cells and mast cell formation, but not for erythroid and myeloid terminal differentiation. Blood 89 (1997) 3636-3643
83. Shivdasani R.A., and Orkin S.H. Erythropoiesis and globin gene expression in mice lacking the transcription factor NF-E2. Proc Natl Acad Sci USA 92 (1995) 8690-8694
84. Tsang A.P., Visvader J.E., Turner C.A., Fujiwara Y., Yu C., Weiss M.J., et al. FOG, a multitype zinc finger protein, acts as a cofactor for transcription factor GATA-1 in erythroid and megakaryocytic differentiation. Cell 90 (1997) 109-119
85. Wadman I.A., Osada H., Grutz G.G., Agulnick A.D., Westphal H., Forster A., et al. The LIM-only protein Lmo2 is a bridging molecule assembling an erythroid, DNA-binding complex which includes the TAL1, E47, GATA-1 and Ldb1/NLI proteins. EMBO J 16 (1997) 3145-3157
86. Blobel G.A., Nakajima T., Eckner R., Montminy M., and Orkin S.H. CREB-binding protein cooperates with transcription factor GATA-1 and is required for erythroid differentiation. Proc Natl Acad Sci USA 95 (1998) 2061-2066
87. Gregory R.C., Taxman D.J., Seshasayee D., Kensinger M.H., Bieker J.J., and Wojchowski D.M. Functional interaction of GATA1 with erythroid Kruppel-like factor and Sp1 at defined erythroid promoters. Blood 87 (1996) 1793-1801
88. Matsumura I., Kawasaki A., Tanaka H., Sonoyama J., Ezoe S., Minegishi N., et al. Biologic significance of GATA-1 activities in Ras-mediated megakaryocytic differentiation of hematopoietic cell lines. Blood 96 (2000) 2440-2450